Weekly Paclitaxel versus the Standard 3-Weekly Schedule in Patients with Non-Small Cell Lung Cancer
نویسندگان
چکیده
منابع مشابه
Carboplatin plus weekly paclitaxel treatment in non-small cell lung cancer patients with interstitial lung disease.
BACKGROUND Since advanced non-small cell lung cancer (NSCLC) patients with the interstitial lung disease (ILD) have been excluded from clinical trials, it is uncertain whether chemotherapy really provides a benefit to these patients. PATIENTS AND METHODS Fifteen advanced NSCLC patients with ILD that was detected on the chest X-rays were enrolled in this study. Carboplatin plus paclitaxel was ...
متن کاملPhase II study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer.
BACKGROUND To date, no phase II trial of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer (NSCLC) has been published. The safety and efficacy of the combination of nedaplatin and weekly paclitaxel in patients with NSCLC was examined. PATIENTS AND METHODS Patients with previously untreated NSCLC, either stage IIIB with pleural effusion or stage IV, were eli...
متن کاملRandomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial.
BACKGROUND Docetaxel is a widely accepted second-line treatment in advanced non-small-cell lung cancer (NSCLC) with a risk of myelotoxicity. This study evaluated the efficacy and toxicity profile of two docetaxel regimens in NSCLC patients who had failed first-line non-docetaxel-based chemotherapy. PATIENTS AND METHODS A total of 259 patients from 33 Spanish centers were randomized to receive...
متن کاملCarboplatin and weekly paclitaxel in non-small cell lung cancer patients unfit for or pretreated with chemotherapy.
BACKGROUND Carboplatin-Paclitaxel is one of the most active regimens in non-small cell lung cancer (NSCLC). We assessed the administration of weekly Paclitaxel as second-line chemotherapy, or as first-line chemotherapy in unfit patients. PATIENTS AND METHODS Forty-eight patients received Carboplatin at the dose of 6 x area under the concentration-time curve (AUC) on day 1 and Paclitaxel 100 m...
متن کاملA phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer.
PURPOSE Our aim was to evaluate the efficacy, toxicity, and pharmacokinetic behavior of single-agent paclitaxel given weekly to elderly patients with lung cancer. EXPERIMENTAL DESIGN Previously untreated patients with stage IIIB/IV non-small cell lung cancer were eligible for the study if they were at least 70 years of age and had preserved organ function. Paclitaxel was administered over 1 h...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2012
ISSN: 0923-7534
DOI: 10.1016/s0923-7534(20)33776-5